RFA
ANTH

Reilly Financial Advisors’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Reilly Financial Advisors’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-25
Closed – – 980
2016
Q4 		$0 Buy
+25
New +$433 ﹤0.01% 945

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Reilly Financial Advisors's ANTH Position: Q1 2017 in Review

Reilly Financial Advisors sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2017, closing a stake of 25 shares.

Reilly Financial Advisors first reported a position in ANTH in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 60 funds tracked by Wall St. Rank hold ANTH as of Q1 2017.

  • Reilly Financial Advisors reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Reilly Financial Advisors sold 25 Anthera Pharmaceuticals, Inc. shares in Q1 2017.
  • Reilly Financial Advisors first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Reilly Financial Advisors's Anthera Pharmaceuticals, Inc. position peaked at $0 in Q4 2016.
  • 60 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2017.

Based on Reilly Financial Advisors's 13F filing for Q1 2017, filed 18 Apr 2017.